No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Hisamitsu Pharmaceutical Co., Inc. is a Japanese enterprise specializing in the development, manufacturing, and distribution of a wide array of healthcare solutions. Its extensive product catalog includes pharmaceuticals, medical devices, quasi-drugs, and cosmetics, catering to markets in Japan, the United States, and Asia. The company is particularly recognized for its comprehensive range of external pain relief medications, featuring popular brands such as SALONPAS, NOBINOBI, SALONSIP, AIR, and FEITAS. Additionally, Hisamitsu offers various transdermal patches for pain and inflammation, including MOHRUS TAPE, MOHRUS PAP XR, FENTOS Tapes, NEOXY Tapes, Abstral, ALLESAGA Tapes, HARUROPI Tapes, and MENOAID Combipatch. Beyond pain management, its portfolio addresses other conditions with products like BUTENALOCK for athlete's foot and ALLEGRA FX for allergy and sinus symptoms. Specialized therapeutic patches for female hormone regulation, asthma, overactive bladders, and the HFT-290 patch for cancer pain further highlight its diverse pharmaceutical offerings. Founded in Tosu, Japan, in 1847, Hisamitsu Pharmaceutical boasts a rich history in the industry.
www.hisamitsu.co.jpNo one on the platform currently holds 4530.T.
No tracked institution reports a position in 4530.T as of their last filing.
No one on the platform has traded 4530.T yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 8.0% | 7.0% | 9.1% | — | — | — |
| Rev. Growth % | 4.5% | 7.3% | ||||
| Profit Margin % | 11.8% | 10.5% | 11.4% | |||
| Free Cash Flow Margin % | 5.8% | 5.9% | 8.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $168.5B | +4.0% | $292.60 | $292.60–$292.60 | — | 1 |
| 2028 | $175.5B | +4.2% | $319.10 | $319.10–$319.10 | — | 1 |
| 2029 | $183.5B | +4.6% | $361.00 | $361.00–$361.00 | — | 1 |
| 2030 | $192.0B | +4.6% | $404.00 | $404.00–$404.00 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-04-13 | $50.60 | $102.79 | +103.1% |
| 2026-01-06 | $55.10 | $68.77 | +24.8% |
| 2025-10-09 | $60.00 | $63.95 | +6.6% |
| 2025-07-10 | $68.80 | $35.14 | -48.9% |
| 2025-04-10 | $49.60 | $105.45 | +112.6% |
| 2025-01-09 | $53.50 | $62.31 | +16.5% |
| 2024-10-10 | $62.00 | $58.76 | -5.2% |
| 2024-07-11 | $53.20 |
| $63.89 |
| +20.1% |
| +1.44% |
| $147.1B |
| — |
| 4540.TTsumura & Co. | $3789.00 | +1.94% | $282.5B | — |
| 4547.TKissei Pharmaceutical Co., Ltd. | $4020.00 | +0.75% | $166.6B | — |
Source: Financial Modeling Prep · peers by sector/industry